BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026)

BridgeBio Pharma (BBIO) posted Short term Debt of $547.5 million for Q1 2026, up 14915.99% sequentially from $3.6 million in Q1 2021.

BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026) Analysis & Trends

BridgeBio Pharma has reported Short term Debt for 3 years, with the latest figure at $547.5 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $547.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $547.5 million (changed N/A YoY) and the FY2020 annual result came in at $1.5 million, changed N/A from the prior year.
Short term Debt grew to $547.5 million in Q1 2026 per BBIO's latest filing, from $3.6 million in the prior quarter.
Over five years, Short term Debt peaked at $547.5 million in Q1 2026 and troughed at $547.5 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	BridgeBio Pharma	15.60 Bn	14.89 Bn	228.63 Mn

Download Data